Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | HPGD | P15428 | 3/20 | 0.77 |
| ▸ | USP7 | Q93009 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506246 | 1.00 | NPC1 (0.77) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL20116145 | 0.79 | TLR9 (0.70) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30506252 | 0.79 | TLR9 (0.70) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10040494 | 0.78 | USP7 (0.65) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20661015 | 0.78 | TLR9 (0.68) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL21938901 | 0.76 | HSD17B10 (0.61) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10040533 | 0.76 | USP7 (0.74) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL10619580 | 0.76 | USP7 (0.74) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13135840 | 0.76 | USP7 (0.74) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL407318 | 0.76 | USP7 (0.74) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3700934-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| CN-110099898-A | compound and use thereof | 优曼尼蒂治疗公司 | 2019-08-06 | — | — | CN | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NPC1 72/4885RAB9A 2129/4885KDM4E 2853/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NPC1 72/4885RAB9A 2129/4885KDM4E 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.